Acinetobacter News and Research RSS Feed - Acinetobacter News and Research

New drug is effective against superbug MRSA

New drug is effective against superbug MRSA

"I routinely call hospitals and request their yearly antibiotic susceptibility testing data," said Washington University in St. Louis' Timothy Wencewicz. "The log might say, for example, that they've treated hundreds of patients for Acinetobacter baumanni, a bacterium brought into U.S. hospitals by soldiers wounded in the Iraq war, with 30 different antibiotics. [More]

Seward highlights effectiveness of Stomacher technique and sponge swabs for hygiene monitoring

Seward Ltd., manufacturers of the world leading range of Stomacher paddle blenders and Stomacher® accessories used in sample preparation for microbiological analyses, have highlighted the highly effective use of its Stomacher technology in combination with sponge swabs for hygiene monitoring and biosecurity applications. [More]
FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

FOB Synthesis enters into license agreement with AstraZeneca to treat drug-resistant bacterial infections

FOB Synthesis, Inc. has entered into a research and development option and license agreement with AstraZeneca for the development of a novel antibiotic to treat drug-resistant bacterial infections. [More]

Hot water contamination in hospital taps threatens patient safety

New research finds significantly higher levels of infectious pathogens in water from faucet taps with aerators compared to water from deeper in the plumbing system. Contaminated water poses an increased risk for infection in immunocompromised patients. [More]
Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

Synthetic Biologics prices underwritten public offering of common stock at $1.00 per share

Synthetic Biologics, Inc., a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share. [More]
Researchers identify resistance protein that allows bacteria to survive chlorhexidine

Researchers identify resistance protein that allows bacteria to survive chlorhexidine

Researchers have identified a resistance protein that allows bacteria to survive chlorhexidine, a disinfectant commonly used in wipes, cleansers and mouthwashes in hospitals. [More]
New type of antibiotic kills multidrug-resistant germ common to health care settings

New type of antibiotic kills multidrug-resistant germ common to health care settings

A new type of antibiotic called a PPMO, which works by blocking genes essential for bacterial reproduction, successfully killed a multidrug-resistant germ common to health care settings, UT Southwestern Medical Center researchers report. [More]
FDA promise to "reboot" antibiotic development rules to combat rise in resistance falls short

FDA promise to "reboot" antibiotic development rules to combat rise in resistance falls short

The rise of antibiotic resistance among hospital-acquired infections is greater than the Centers for Disease Control and Prevention found in its 2008 analysis, according to an ahead-of-print article in the journal, Antimicrobial Agents and Chemotherapy. [More]
Study reveals that Hudson River polluted with antibiotic-resistant bacteria

Study reveals that Hudson River polluted with antibiotic-resistant bacteria

The risk of catching some nasty germ in the Hudson River just started looking nastier. Disease-causing microbes have long been found swimming there, but now researchers have documented antibiotic-resistant strains in specific spots, from the Tappan Zee Bridge to lower Manhattan. [More]
BioFire Diagnostics' FilmArray Blood Culture Identification Panel receives FDA clearance

BioFire Diagnostics' FilmArray Blood Culture Identification Panel receives FDA clearance

BioFire Diagnostics, Inc., announced today the FDA clearance of its FilmArray Blood Culture Identification Panel. To date, the 27-target panel is the most comprehensive test to be approved by the FDA. [More]
Scientists find way to attack dangerous bacteria that cause eye infections

Scientists find way to attack dangerous bacteria that cause eye infections

Much as predators attack their prey in the animal world, there are bacteria that consume and kill other bacteria. Scientists are reporting new progress in putting the predator microbes to work - to attack dangerous bacteria that cause eye infections that lead to blindness and have grown resistant to antibiotics. [More]
Cubist receives Fast Track designation from FDA for late-stage antibiotic candidate

Cubist receives Fast Track designation from FDA for late-stage antibiotic candidate

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted the Company's late-stage antibiotic candidate ceftolozane/tazobactam (CXA-201) Fast Track status in the previously granted Qualified Infectious Disease Product indications, Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia and Complicated Urinary Tract Infections. [More]
Study confirms effectiveness of UV-C-emitting device in combating pathogens in hospital environment

Study confirms effectiveness of UV-C-emitting device in combating pathogens in hospital environment

A recent study funded by Centers for Disease Control and Prevention Epicenters Program and published in Infection Control and Hospital Epidemiology ( Deverick H. Anderson , M.D., MPH et al., 2013) supports and expands on previously published studies confirming the effectiveness of an automated UV-C-emitting device to combat the pathogens Clostridium difficile (C. diff.), vancomycin-resistant enterococci (VRE) and Acinetobacter spp. – some of the common culprits of health care-associated infections drawing increased attention for hospitals across the country. [More]

Cubist receives FDA QIDP designation for ceftolozane/tazobactam to treat HABP/ VABP, cUTI

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the company's late-stage antibiotic candidate, ceftolozane/tazobactam, as a Qualified Infectious Disease Product (QIDP) for the indications of Hospital-Acquired Bacterial Pneumonia (HABP)/Ventilator-Associated Bacterial Pneumonia (VABP) and Complicated Urinary Tract Infections (cUTI). [More]

Xellia to develop new antibiotics effective against multi-drug resistant Gram-negative bacteria

Xellia Pharmaceuticals, a fully integrated specialty pharmaceutical company focusing on the global anti-infective market, announced today that it is developing new antibiotics effective against multi-drug resistant (MDR), Gram-negative bacteria. [More]

FDA designates two of Cubist’s Phase 3 antibiotic candidates

Cubist Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated two of the company's Phase 3 antibiotic candidates, CXA-201 (ceftolozane/tazobactam) and CB-315, as Qualified Infectious Disease Products (QIDP). [More]

Current hospital cleaning protocol may be inadequate to rid MDR A. baumannii

Current hospital cleaning protocol may be inadequate to rid patient rooms of multidrug-resistant (MDR) Acinetobacter baumannii, according to a study in the December issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology (APIC). [More]

WellStar Health System implements Xenex’s room disinfection system

WellStar Health System was the first to implement and is the only health system in metro-Atlanta using Xenex Healthcare Services' room disinfection system in its patient and operating rooms. A "green," mercury-free technology, the Xenex system is the fastest, safest and most effective method for the advanced cleaning of hospital rooms, scientifically proven to destroy all major classes of microorganisms that cause hospital acquired infections (HAIs), such as MRSA and Clostridium difficile (C. diff). [More]

Metalloacid surfaces may be answer to hospital-acquired infections

Coating surfaces in metalloacids may help control the spread of hospital-acquired infections, suggest study findings. [More]

Xenex offers room disinfection devices to hospitals hit by Hurricane Sandy

Xenex Healthcare Services, the world leader in UV room disinfection systems, today announced it is making its room disinfection devices available to hospitals affected by Hurricane Sandy. [More]